Back to top
more

Corvus Pharmaceuticals (CRVS)

(Delayed Data from NSDQ)

$4.31 USD

4.31
699,578

+0.18 (4.36%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $4.31 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks News

Zacks Equity Research

3 Reasons Why Corvus Pharmaceuticals (CRVS) is a Great Momentum Stock

Corvus Pharmaceuticals (CRVS) is a solid momentum stock that has a favorable Zacks Rank and is seeing solid earnings estimate revisions.

    Zacks Equity Research

    Top Ranked Momentum Stocks to Buy for April 4th

    Here are four stocks with Zacks Rank #1 (Strong Buy) and strong momentum characteristics for investors to consider today, April 4th:

      Zacks Equity Research

      AstraZeneca's (AZN) Lung Cancer Drug Gets Full FDA Approval

      AstraZeneca plc (AZN) announced that its lung cancer drug, Tagrisso has received full approval from the FDA.

        Tirthankar Chakraborty headshot

        New Strong Buy Stocks for March 31st

        Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday

          Zacks Equity Research

          Top Ranked Momentum Stocks to Buy for March 31st

          Here are four stocks with Zacks Rank #1 (Strong Buy) and strong momentum characteristics for investors to consider today, March 31st:

            Zacks Equity Research

            AstraZeneca's Lung Cancer Drug Tagrisso Approved in China

            AstraZeneca plc (AZN) announced that its lung cancer drug, Tagrisso has received approval in China.

              Zacks Equity Research

              Top Ranked Momentum Stocks to Buy for March 27th

              Here are four stocks with Zacks Rank #1 (Strong Buy) and strong momentum characteristics for investors to consider today, March 27th:

                Zacks Equity Research

                Can the Rally in Corvus Pharmaceuticals (CRVS) Shares Continue?

                Corvus Pharmaceuticals Inc (CRVS) has been on the move lately as the stock has risen by 49.5% in the past four weeks, and it is currently trading well above its 20-Day SMA